MedTrace Logo

Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation

NCT01332097 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2023-03-21

Study results available
· View outcomes & findings →

Summary

This study will assess preliminary parameters of safety and efficacy of a single dose of BCT197 in patients with a Chronic Obstructive Pulmonary Disease (COPD) exacerbation.

Conditions

Interventions

DRUG

BCT197

DRUG

Prednisone placebo

capsules

DRUG

BCT197 placebo

capsules

DRUG

Prednisone

capsules

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Mereo BioPharma

    lead INDUSTRY

Principal Investigators

  • Jacqueline Parkin, PhD FRCP · Mereo BioPharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2013-05-31
Completion
2013-05-31
FDA Drug
Yes

Countries

  • Bulgaria
  • Romania
  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01332097 on ClinicalTrials.gov